MSC therapy for inflammatory bowel disease
- Authors: Konoplyannikov M.A.1,2, Knyazev O.V.3,4, Baklaushev V.P.1
-
Affiliations:
- Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies FMBA of Russia
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Moscow Clinical Scientific Center
- State Scientific Centre of Coloproctology
- Issue: Vol 12, No 1 (2021)
- Pages: 53-65
- Section: Reviews
- URL: https://journals.rcsi.science/clinpractice/article/view/64530
- DOI: https://doi.org/10.17816/clinpract64530
- ID: 64530
Cite item
Abstract
Inflammatory bowel disease (IBD) belongs to the group of diseases characterized by idiopathic inflammation of the digestive tract organs. Two basic IBD types are distinguished: ulcerative colitis and Crohn’s disease. The IBD symptoms including vomiting and diarrhea, abdominal pain, rectal bleeding, anemia have a significant negative impact on the general patient’s state of health. Besides, IBD patients are susceptible to the risk of a number of serious diseases such as colorectal cancer, thrombosis and primary sclerosing cholangitis. More than 4 million people in the USA and Europe suffer from IBD, with 70000 new cases diagnosed yearly in the USA only.
In some cases, a surgical removal of the damaged digestive tract fragments is required to treat severe IBD forms. However, drug therapy of IBD has mainly been used in the last decades. The rate of remission with application of traditional IBD therapy is estimated as 20-30%, and is still no higher than 50% with the combined therapy. Cell therapy has been proven to be a very promising approach in the IBD treatment. In our review, we discuss mesenchymal stromal cells (MSC) and the most important preclinical and clinical results of their application for the IBD therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Mikhail A. Konoplyannikov
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies FMBA of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: mkonopl@mail.ru
ORCID iD: 0000-0003-1180-2343
SPIN-code: 9211-6391
Cand. Sci. (Biol.)
Russian Federation, 28, Orekhovy blvd, Moscow, 115682; MoscowOleg V. Knyazev
Moscow Clinical Scientific Center; State Scientific Centre of Coloproctology
Email: oleg7@bk.ru
ORCID iD: 0000-0001-7250-0977
SPIN-code: 3268-0360
Dr. Sci. (Med.)
Russian Federation, Moscow; MoscowVladimir P. Baklaushev
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies FMBA of Russia
Email: serpoff@gmail.com
ORCID iD: 0000-0003-1039-4245
SPIN-code: 3968-2971
Dr. Sci. (Med.)
Russian Federation, 28, Orekhovy blvd, Moscow, 115682References
- Sairenji T, Collins KL, Evans DV. An update on inflammatory bowel disease. Prim Care. 2017;44(4):673–692. doi: 10.1016/j.pop.2017.07.010
- Guindi M, Riddell RH. Indeterminate colitis. J Clin Pathol. 2004;57(12):1233–1244. doi: 10.1136/jcp.2003.015214
- Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307–317. doi: 10.1038/nature10209
- The facts about inflammatory bowel diseases. The Crohn’s & Colitis Foundation of America (CCFA); 2014. Avalable from: https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf
- GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30. doi: 10.1016/S2468-1253(19)30333-4
- Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010;24(Suppl 1):3–14. doi: 10.2165/11586290-000000000-00000
- Ocansey DK, Qiu W, Wang J, et al. The Achievements and Challenges of Mesenchymal Stem Cell-Based Therapy in Inflammatory Bowel Disease and Its Associated Colorectal Cancer. Stem Cells Int. 2020;2020:7819824. doi: 10.1155/2020/7819824
- Tolar J, Le Blanc K, Keating A, et al. Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells. 2010;28(8):1446–1455. doi: 10.1002/stem.459
- Williams JT, Southerland SS, Souza J, et al. Cells isolated from adult human skeletal muscle capable of differentiating into multiple mesodermal phenotypes. Am Surg. 1999; 65:22–26.
- Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implication for cell-based therapies. Tissue Engl. 2001;7(2):211–228. doi: 10.1089/107632701300062859
- Gronthos S, Arthur A, Bartold PM, et al. A method to isolate and culture expand human dental pulp stem cells. J Methods Mol Biol. 2011;698:107–121. doi: 10.1007/978-1-60761-999-4_9
- Prockop D. Repair of tissues by adult stem/progenitor cells [MSCs]: controversies, myths, and changing paradigms. Mol Ther. 2009;17(6):939–946. doi: 10.1038/mt.2009.62
- Lv FJ, Tuan RS, Cheung KM, et al. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells. 2014;32(6):1408–1419. doi: 10.1002/stem.1681
- Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11–15. doi: 10.1016/j.stem.2011.06.008
- Wang S, Miao Z, Yang Q, et al. The dynamic roles of mesenchymal stem cells in colon cancer. Can J Gastroenterol Hepatol. 2018;2018:7628763. doi: 10.1155/2018/7628763
- Caplan AI. MSCs: The sentinel and safe-guards of injury. J Cell Physiol. 2016;231(7):1413–1416. doi: 10.1002/jcp.25255
- Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392–402. doi: 10.1016/j.stem.2013.09.006
- Spaggiari GM, Capobianco A, Abdelrazik HF, et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood. 2008;111(3):1327–1333. doi: 10.1182/blood-2007-02-074997
- Terai S, Tsuchiya A. Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis. J Gastroenterol. 2017;52(2):129–140. doi: 10.1007/s00535-016-1258-1
- Yabana T, Arimura Y, Tanaka H, et al. Enhancing epithelial engraftment of rat mesenchymal stem cells restores epithelial barrier integrity. J Pathol. 2009;218:350–359. doi: 10.1002/path.2535
- Dias CB, Milanski M, Portovedo M, et al. Defective apoptosis in intestinal and mesenteric adipose tissue of Crohn’s disease patients. PLoS One. 2014;9(6):e98547. doi: 10.1371/journal.pone.0098547
- Akiyama K, Chen C, Wang D, et al. Mesenchymal-stem cell-induced immunoregulation involves FAS-ligand-/FASmediated T cell apoptosis. Cell Stem Cell. 2012;10(5):544–555. doi: 10.1016/j.stem.2012.03.007
- Sisakhtnezhad S, Alimoradi E, Akrami H. External factors influencing mesenchymal stem cell fate in vitro. Eur J Cell Biol. 2017;96(1):13–33. doi: 10.1016/j.ejcb.2016.11.003
- Chen Q, Yan L, Wang CZ, et al. Mesenchymal stem cells alleviate TNBS-induced colitis by modulating inflammatory and autoimmune responses. World J Gastroenterol. 2013;19(29):4702–4717. doi: 10.3748/wjg.v19.i29.4702
- Hidalgo-Garcia L, Galvez J, Rodriguez-Cabezas ME, Anderson PO. Can a conversation between mesenchymal stromal cells and macrophages solve the crisis in the inflamed intestine? Front Pharmacol. 20186;9:179. doi: 10.3389/fphar.2018.00179
- Jo H, Eom YW, Kim HS, et al. Regulatory dendritic cells induced by mesenchymal stem cells ameliorate dextran sodium sulfate-induced chronic colitis in mice. Gut Liver. 2018;12(6):664–673. doi: 10.5009/gnl18072
- Liu J, Liu Q, Chen X. The immunomodulatory effects of mesenchymal stem cells on regulatory B cells. Front Immunol. 2020;11:1843. doi: 10.3389/fimmu.2020.01843
- Самойлова Е.М., Кальсин В.А., Беспалова В.А., и др. Экзосомы — от биологии к клинике // Гены и клетки. 2017. Т. 12, № 4. С. 7–19. [Samoilova EM, Kalsin VA, Bespalova VA, et al. Exosomes — from biology to the clinic. Genes & Cells. 2017;12(4):7–19. (In Russ).] doi: 10.23868/201707024
- Zhao T, Sun F, Liu J, et al. Emerging role of mesenchymal stem cell-derived exosomes in regenerative medicine. Curr Stem Cell Res Ther. 2019;14(6):482–494. doi: 10.2174/1574888X14666190228103230
- Mianehsaz E, Mirzaei HR, Mahjoubin-Tehran M, et al. Mesenchymal stem cell-derived exosomes: a new therapeutic approach to osteoarthritis? Stem Cell Res Ther. 2019;10(1):340. doi: 10.1186/s13287-019-1445-0
- Mendt M, Rezvani K, Shpall E. Mesenchymal stem cell-derived exosomes for clinical use. Bone Marrow Transplant. 2019;54(Suppl 2):789–792. doi: 10.1038/s41409-019-0616-z
- Mao F, Yunbing Wu, Xudong Tang, et al. Exosomes derived from human umbilical cord mesenchymal stem cells relieve inflammatory bowel disease in mice. Biomed Res Int. 2017;2017:5356760. doi: 10.1155/2017/5356760
- Yang R, Huang H, Cui S, et al. IFN-γ promoted exosomes from mesenchymal stem cells to attenuate colitis via miR-125a and miR-125b. Cell Death Dis. 2020;11(7):603. doi: 10.1038/s41419-020-02788-0
- Ko JZ, Johnson S, Dave M. Efficacy and safety of mesenchymal stem/stromal cell therapy for inflammatory bowel diseases: an up-to-date systematic review. Biomolecules. 2021;11(1):82. doi: 10.3390/biom11010082
- Panés J, García-Olmo D, Van Assche G, et al; ADMIRE CD Study Group Collaborators. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2018;154(5):1334–1342.e4. doi: 10.1053/j.gastro.2017.12.020
- Herreros MD, Garcia-Olmo D, Guadalajara HT, et al. Stem cell therapy: a compassionate use program in perianal fistula. Stem Cells Int. 2019;2019:6132340. doi: 10.1155/2019/6132340
- Garcia-Olmo D, Garcia-Arranz M, Herreros D, et al. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48(7):1416–1423. doi: 10.1007/s10350-005-0052-6
- McNevin MS, Lee PY, Bax TW. Martius flap: an adjunct for repair of complex, low rectovaginal fistula. Am J Surg. 2007;193(5):597–599. doi: 10.1016/j.amjsurg.2007.01.009
- Cho YB, Park KJ, Yoon SN, et al. Long-Term results of adipose-derived stem cell therapy for the treatment of Crohn’s fistula: ASCs for the treatment of Crohn’s fistula. Stem Cells Transl Med. 2015;4(5):532–537. doi: 10.5966/sctm.2014-0199
- Scott LJ. Darvadstrocel: a review in treatment-refractory complex perianal fistulas in Crohn’s disease. BioDrugs. 2018;32(6):627–634. doi: 10.1007/s40259-018-0311-4
- Cao Y, Su Q, Zhang B, et al. Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review. Stem Cell Res Ther. 2021;12(1):32. doi: 10.1186/s13287-020-02095-7
- Hu J, Zhao G, Zhang L, et al. Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis. Exp Ther Med. 2016;12(5):2983–2989. doi: 10.3892/etm.2016.3724
- Zhang J, Lv S, Liu X, et al. Umbilical cord mesenchymal stem cell treatment for Crohn’s disease: a randomized controlled clinical trial. Gut and Liver. 201812(1):73–78. doi: 10.5009/gnl17035
- Князев О.В., Парфенов А.И., Коноплянников А.Г., Болдырева О.Н. Использование мезенхимальных стромальных клеток в комплексной терапии язвенного колита // Терапевтический архив. 2016. Т. 88, № 2. C. 44–48. [Knyazev OV, Parfenov AI, Konoplyannikov AG, Boldyreva ON. The use of mesenchymal stromal cells in the complex therapy of ulcerative colitis. Therapeutic archive. 2016;88(2):44–48. (In Russ).]
- Князев О.В., Каграманова А.В., Фадеева Н.А., и др. Мезенхимальные стромальные клетки костного мозга и азатиоприн в терапии болезни Крона // Терапевтический архив. 2018. Т. 90. № 2. C. 47–52. [Knyazev OV, Kagramanova AV, Fadeeva NA, et al. Bone marrow mesenchymal stromal cells and azathioprine in the treatment of Crohn’s disease. Therapeutic archive. 2018;90(2):47–52. (In Russ).] doi: 10.26442/terarkh201890247-52
- Князев О.В., Фадеева Н.А., Каграманова А.В., и др. Клеточная терапия перианальных проявлений болезни Крона // Терапевтический архив. 2018. Т. 90, № 3. C. 60–66. [Knyazev OV, Fadeeva NA, Kagramanova AV, et al. Cell therapy of the perianal manifestations of Crohn’s disease. Therapeutic archive. 2018;90(3):60–66. (In Russ).] doi: 10.26442/terarkh201890360-66